Skip to main content
    C

    Charles River Laboratories (CRL)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $335.46
    -2.51 (-0.74%)

    Market Cap: $16.19B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Charles River Laboratories (CRL) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Charles River Laboratories (CRL) trades at 31.8x trailing earnings and 4.0x sales. Its P/E of 31.8x is above its 5-year median of 19.4x. Its forward P/E is 26.6x. The median P/E across 10 similar companies is 25.3x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 19.5% higher over the next year. Its free cash flow yield is 2.5%.

    MultipleValue
    P/E (trailing)31.8x
    Forward P/E26.6x
    Price to sales4.0x
    Price to book5.0x
    EV/EBITDA63.0x
    Price to FCF40.1x
    EV/FCF45.7x
    PEG0.1
    FCF yield2.5%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 55.1% above 20.5x, its P/S is 48.1% above 2.7x and its P/B is 11.1% above 4.5x.

    MultipleCurrent5-year median10-year median
    P/E31.8x19.4x20.5x
    P/S4.0x2.6x2.7x
    P/B5.0x3.2x4.5x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 16.7x in 2016 to 36.5x in 2021.

    Year endPriceP/EP/SP/B
    2025$199.4819.4x2.5x3.1x
    2024$184.6017.9x2.3x2.7x
    2023$236.4022.2x2.9x3.4x
    2022$217.9019.6x2.8x3.8x
    2021$376.7836.5x5.4x7.7x
    2020$249.8630.7x4.3x6.0x
    2019$152.7622.7x2.9x4.7x
    2018$113.1818.8x2.4x4.2x
    2017$109.4520.7x2.8x5.0x
    2016$76.1916.7x2.2x4.4x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CRL

    What is CRL's forward P/E ratio?

    Charles River Laboratories has a forward P/E ratio of 26.6x.

    Is CRL stock overvalued?

    GNG's valuation label for CRL is Overvalued. Its P/E of 31.8x compares with a median of 25.3x across 10 similar companies.

    What is CRL's price to sales ratio?

    Charles River Laboratories has a price to sales ratio of 4.0x.

    What is Charles River Laboratories's average P/E ratio over 5 years?

    Charles River Laboratories's median P/E over the last 5 years is 19.4x, from 60 month-end values through Oct 2026.

    What is CRL's PEG ratio?

    Charles River Laboratories has a PEG ratio of 0.1.